Allergy Therapeutics PLC Hardman: Clinical development towards submission
07 March 2018 - 8:30PM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
07 March 2018
Hardman Research: Clinical development towards submission
Clinical development towards submission: AGY is a
long-established specialist in the prevention, diagnosis and
treatment of allergies. Pollinex Quattro (PQ) Grass, the
subcutaneous allergy immunotherapy (AIT), continues to gain market
share despite being available in the EU only on a 'Named Patient'
basis. The Phase III trial, designed to obtain approval for PQ
Birch as a biologic in Europe, is well advanced, and the Phase II
PQ Grass trial will report data shortly. As explained in the
February trading update, underlying 1H'18 sales growth, although
weaker than expected due to a low pollen season in central Europe,
suggests that AGY has continued to make market share gains.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/agy---interims---7th-march-2018.pdf
To contact us: Contacts: mh@hardmanandco.com
Hardman & Co Dr Martin dmh@hardmanandco.com
35 New Broad Street Hall gp@hardmanandco.com
London Dr Dorothea
EC2M 1NH Hill
www.hardmanandco.com Dr Gregoire
Follow us on Twitter Pave
@HardmanandCo
+44 20 7194
7622
About Hardman & Co: For the past 21 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGUBGWUPRGQQ
(END) Dow Jones Newswires
March 07, 2018 04:30 ET (09:30 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024